Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060932 | 0.90 | FFAR1 (0.53) | FFAR1CD274 | |
| SCHEMBL13222683 | 0.90 | FFAR1 (0.53) | FFAR1CD274 | |
| SCHEMBL15473917 | 0.87 | FFAR1 (0.46) | FFAR1CD274 | |
| SCHEMBL15471504 | 0.87 | FFAR1 (0.46) | FFAR1CD274 | |
| SCHEMBL10291329 | 0.83 | FFAR1 (0.47) | FFAR1CD274 | |
| SCHEMBL13243698 | 0.83 | FFAR1 (0.47) | FFAR1CD274 | |
| SCHEMBL9921459 | 0.81 | CD274 (0.44) | FFAR1CD274 | |
| SCHEMBL9921458 | 0.81 | CD274 (0.44) | FFAR1CD274 | |
| SCHEMBL9921301 | 0.78 | FFAR1 (0.45) | FFAR1CD274 | |
| SCHEMBL9921261 | 0.78 | FFAR1 (0.45) | FFAR1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399507-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2215068-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2009058237-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216694-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | FFAR1 19/4885CD274 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.